CE DESK 
Eli Lilly India appoints Pranav Shroff as Director of Marketing to lead diabetes, oncology, and immunology portfolio strategies amid growing chronic disease prevalence.
Eli Lilly and Company (India) Pvt. Ltd. has appointed Pranav Shroff as Director of Marketing, strengthening its leadership to drive growth across high-priority therapeutic areas including diabetes, oncology, immunology, and neuroscience. Shroff will oversee brand strategy, market access, digital transformation, and omni-channel customer engagement for Lilly’s premium pharmaceutical portfolio.
With extensive experience in pharmaceutical marketing across MNCs and Indian majors, Shroff brings proven success launching innovative therapies, building KOL relationships, and navigating India’s complex regulatory-commercial landscape. His mandate includes accelerating Lilly’s diabetes franchise—anchored by blockbuster GLP-1 therapies—while expanding access to precision oncology and autoimmune treatments amid rising chronic disease burdens.
India represents Lilly’s fastest-growing emerging market, fueled by affluent urban adoption of novel biologics and government diabetes control initiatives. Shroff’s role becomes critical as Lilly invests ₹5,000 crore+ in domestic R&D and manufacturing to localize production and reduce import dependence.
The appointment aligns with Lilly’s “Patient First” philosophy, emphasizing evidence-based solutions, patient support programs, and healthcare partnerships. Shroff will collaborate with medical affairs and sales teams to enhance HCP engagement through data-driven insights and CME programs targeting Tier 1-2 prescribers.
This strategic hire positions Lilly to capture leadership in high-growth segments while reinforcing its reputation for scientific excellence and innovation-led patient outcomes.
